Bristol Myers Squibb discloses results from it's Phase I Breakfree-2 trial of CAR-T therapy zola-cel for multiple sclerosis.
|Articles|March 1, 2017
Median Cost Per Patient for Orphan Drugs is 5.5 Times Higher Than Non-Orphan Drugs
March 01, 2017
Advertisement
A new report reveals the orphan drug market has grown at approximately double the overall growth of the prescription market.
Highlights of the
- Worldwide orphan drug sales forecast to total $209bn (CAGR 2017 to 2022:+11.1%)
- Orphan drugs set to be 21.4% of worldwide prescription sales by 2022 (excluding generics)
- Median cost per patient 5.5 times higher for orphan drugs compared to non-orphan
- Celgene set to climb to number one position in orphan drug sales to 2022
- Shire to be largest company by sales in the orphan non-oncology space in 2022
- AstraZeneca, Abbvie and Johnson & Johnson set to march up the orphan drug sales ranking table
- Revlimid (lenalidomide) No.1 orphan drug in 2022
- Opdivo (nivolumab) No.1 orphan drug in Europe in 2022
- Orphan drugs forecast to account for 55% of the cumulative value of the European pipeline to 2022
- Axicabtagene Ciloleucel (Kite Pharma) is most valuable R&D orphan drug
- First decline since 2012 for FDA orphan designations in 2016 with 333; Record number of applications made to the FDA for orphan designation in 2016
The “EvaluatePharma Orphan Drug Report 2017” can be downloaded at:
Advertisement
Related to this article
Pharmaceutical and health economist Dr. Nadine Zawadzki, Senior Director, FTI Consulting joins the Ron Lanton Report to discuss how value is defined and measured across healthcare.
The Treasury Department is proposing rules to add biotechnology to its Outbound Investment Security Program under the COINS Act.
Lilly’s Foundayo receives a positive CHMP opinion for obesity and type 2 diabetes — putting the oral GLP-1 pill on course for EU approval.
Astellas gains an option on Audax’s IL-12 antibody-cytokine fusion DAX-044, while EVERSANA acquires London-based health economics firm Estima Scientific.
Shionogi’s Dr. Draica on why preventative antivirals matter — and how its HIV and flu prevention heritage shaped XOCOVA’s post-exposure focus.
The infrastructure decisions companies make today could determine how quickly they capitalize on new computational capabilities
Brox.AI’s Hamish Brocklebank on three levels of digital clone use cases — from HCP content testing and GLP-1 price sensitivity modeling to simulating physician adoption after FDA approval.
Advertisement
Advertisement
Trending on PharmExec
1
The Next Biopharma Revolution: Quantum Computing
2
Roundup: Teva Acquires BXCL501 for $57.5 Million Upfront, Rumi Therapeutics Enters Option Agreement for Fragile X PDE2 Inhibitor From Enthorin
3
How Medications like XOCOVA Prevent Illness After Exposure to COVID-19
4
Bristol Myers Squibb Discloses Patient Death in CAR-T Multiple Sclerosis Trial
5